URGN UroGen Pharma Ltd
- 12.880
- +0.180+1.42%
- 12.880
- 0.0000.00%
UroGen Pharma Ltd News
TD Cowen Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Announces Target Price $35
UroGen Pharma Analyst Ratings
EF Hutton Maintains Buy on UroGen Pharma, Maintains $25 Price Target
UroGen Pharma Price Target Maintained With a $25.00/Share by EF Hutton
UroGen Pharma Analyst Ratings
TD Cowen Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating
Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $40
H.C. Wainwright Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $60
H.C. Wainwright Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $60
EF Hutton Initiates UroGen Pharma Ltd(URGN.US) With Buy Rating, Announces Target Price $25
UroGen Pharma Analyst Ratings
H.C. Wainwright Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $60
Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $40
Guggenheim Initiates UroGen Pharma Ltd(URGN.US) With Buy Rating, Announces Target Price $40
UroGen Pharma Analyst Ratings
H.C. Wainwright Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $60
Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $40
H.C. Wainwright Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $60
UroGen Pharma Analyst Ratings
Goldman Sachs Maintains UroGen Pharma Ltd(URGN.US) With Hold Rating, Maintains Target Price $22
Analysis
Price Target
No Data
No Data